Literature DB >> 31726481

Adrenal gland-released vasostatin-I is a myocardial depressant factor.

Francis Schneider1,2,3, Vincent Castelain1, Jean-Etienne Herbrecht1, Sophie Hellé2,3, Marie-Hélène Metz-Boutigue2,3.   

Abstract

Pheochromocytoma crisis is an exceptional consequence of the release of storage vesicles of the adrenal medulla. It is complicated by fulminant adrenergic myocarditis. It offers a unique opportunity to detect inotropic negative factors from neuroendocrine origin. Our objectives were (a) to describe a pheochromocytoma crisis, (b) to investigate in vivo myocardial depressant activities for the N-terminal 1-76 Chromogranin A-derived peptide, vasostatin-I (VS-I). A patient with a pheochromocytoma crisis was treated, including extracorporeal membrane oxygenation, until mass resection. Plasma concentrations of VS-I were time-dependently assessed with a specific immunoassay; correlations with invasive cardiovascular parameters were investigated. Increased VS-I concentrations were observed over 7 days until tumour resection. VS-I concentrations correlated positively with Chromogranin A levels, negatively with cardiac output and left ventricular stroke work index, but not with heart rate. This case illustrates the pharmacokinetics of VS-I in a pheochromocytoma crisis. It highlights myocardial depressant activity for this peptide at high concentrations.
© 2019 The British Pharmacological Society.

Entities:  

Keywords:  Chromogranin A; myocardial depressant factor; pheochromocytoma, crisis; vasostatin-I

Year:  2020        PMID: 31726481      PMCID: PMC7098871          DOI: 10.1111/bcp.14173

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Vasostatin-I, a chromogranin A-derived peptide, in non-selected critically ill patients: distribution, kinetics, and prognostic significance.

Authors:  Francis Schneider; Charlotte Bach; Hélène Chung; Luca Crippa; Thomas Lavaux; Pierre-Edouard Bollaert; Michel Wolff; Angelo Corti; Anne Launoy; Xavier Delabranche; Thierry Lavigne; Nicolas Meyer; Patrick Garnero; Marie-Hélène Metz-Boutigue
Journal:  Intensive Care Med       Date:  2012-06-16       Impact factor: 17.440

2.  Characterization of a myocardial depressant factor present in hemorrhagic shock.

Authors:  A M Lefer; R Cowgill; F F Marshall; L M Hall; E D Brand
Journal:  Am J Physiol       Date:  1967-08

3.  Adrenal gland-released vasostatin-I is a myocardial depressant factor.

Authors:  Francis Schneider; Vincent Castelain; Jean-Etienne Herbrecht; Sophie Hellé; Marie-Hélène Metz-Boutigue
Journal:  Br J Clin Pharmacol       Date:  2020-02-03       Impact factor: 4.335

4.  Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function.

Authors:  Maurizio Pieroni; Angelo Corti; Bruno Tota; Flavio Curnis; Tommaso Angelone; Barbara Colombo; Maria Carmela Cerra; Fulvio Bellocci; Filippo Crea; Attilio Maseri
Journal:  Eur Heart J       Date:  2007-03-27       Impact factor: 29.983

5.  Antiarrhythmic effects of vasostatin-1 in a canine model of atrial fibrillation.

Authors:  Stavros Stavrakis; Benjamin J Scherlag; Youqi Fan; Yu Liu; Qiming Liu; Jun Mao; Heng Cai; Ralph Lazzara; Sunny S Po
Journal:  J Cardiovasc Electrophysiol       Date:  2012-04-04

6.  Endothelium-derived nitric oxide mediates the antiadrenergic effect of human vasostatin-1 in rat ventricular myocardium.

Authors:  Maria Pia Gallo; Renzo Levi; Roberta Ramella; Alessia Brero; Ombretta Boero; Bruno Tota; Giuseppe Alloatti
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-02-09       Impact factor: 4.733

7.  Chromofungin, CgA47-66-derived peptide, produces basal cardiac effects and postconditioning cardioprotective action during ischemia/reperfusion injury.

Authors:  Elisabetta Filice; Teresa Pasqua; Anna Maria Quintieri; Patrizia Cantafio; Francesco Scavello; Nicola Amodio; Maria Carmela Cerra; Céline Marban; Francis Schneider; Marie-Hélène Metz-Boutigue; Tommaso Angelone
Journal:  Peptides       Date:  2015-07-04       Impact factor: 3.750

8.  The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide.

Authors:  M C Cerra; M P Gallo; T Angelone; A M Quintieri; E Pulerà; E Filice; B Guérold; P Shooshtarizadeh; R Levi; R Ramella; A Brero; O Boero; M H Metz-Boutigue; B Tota; G Alloatti
Journal:  FASEB J       Date:  2008-08-12       Impact factor: 5.191

9.  Cytoskeleton mediates negative inotropism and lusitropism of chromogranin A-derived peptides (human vasostatin1-78 and rat CgA₁₋₆₄) in the rat heart.

Authors:  Tommaso Angelone; Anna Maria Quintieri; Yannich Goumon; Valentina Di Felice; Elisabetta Filice; Alfonsina Gattuso; Rosa Mazza; Angelo Corti; Bruno Tota; Marie-Hélène Metz-Boutigue; Maria Carmela Cerra
Journal:  Regul Pept       Date:  2009-11-05

10.  Evaluation of a new immunoassay for chromogranin A measurement on the Kryptor system.

Authors:  R H P van der Knaap; D J Kwekkeboom; C R B Ramakers; Y B de Rijke
Journal:  Pract Lab Med       Date:  2015-03-10
View more
  2 in total

1.  Adrenal gland-released vasostatin-I is a myocardial depressant factor.

Authors:  Francis Schneider; Vincent Castelain; Jean-Etienne Herbrecht; Sophie Hellé; Marie-Hélène Metz-Boutigue
Journal:  Br J Clin Pharmacol       Date:  2020-02-03       Impact factor: 4.335

2.  Protective effect of vasostatin-1 plasmid-like nanoparticles on aortic aneurysm and its mechanism.

Authors:  Pingshan Wang; Wei Wang; Xingxing Peng; Fugui Ruan; Shiyao Yang
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.